HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Costa, J.-M. Articles by Gautier, E. Search for Related Content PubMed PubMed Citation Articles by Costa, J.-M. Articles by Gautier, E. Related Collections Molecular Diagnostics and Genetics Pediatric Clinical Chemistry

Fetal Expressed Gene Analysis in Maternal Blood: A New Tool for Noninvasive Study of the Fetus

¹ Centre de Diagnostic Prénatal, American Hospital of Paris, 63 bd Victor Hugo, 92200 Neuilly-sur-Seine, France

² Maternité, Hôpital Necker-Enfants Malades, 75015 Paris, France

³ Laboratoire de Génétique Moléculaire, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, 75006 Paris, France

^aauthor for correspondence: fax 33-1-46-41-26-56, e-mail jean-marc.costa@ahparis.org

The first 20% of the full text of this article appears below.

Noninvasive approaches to prenatal diagnosis can avoid the risk of fetal loss associated with invasive procedures such as chorionic villus sampling, amniocentesis, and cordocentesis. Isolation of fetal cells from maternal blood requires further improvements before it can be applied in a clinical setting (1), but the reliability of cell-free fetal DNA analysis in maternal plasma or serum is now well established (2)(3)(4). As a result, it is currently used in specialized centers for the determination of fetal sex and fetal RhD status for the management of pregnant women at risk for X-linked disorders (5) or RhD alloimmunization (6). Because fetal DNA in maternal serum is circulating in an excess background of maternal DNA, clinical applications are restricted mainly to the detection of fetal sequences distinct from the mother’s DNA sequences.

Fetal RNA in maternal blood may be an alternative source of fetal nucleic acids. Al-Mufti et al. (7) detected specific RhD mRNA in mononuclear fetal cells isolated from blood of RhD-negative pregnant women, and Lo’s group demonstrated the presence of Y-chromosome-specific (ZFY) mRNA in maternal plasma of women carrying a male fetus (8). These two applications, however, again require fetal sequences that differ from the mother’s.

We have investigated the presence in maternal blood of fetal transcripts that may have the same sequence as that of the mother. Human chorionic gonadotropin (hCG) mRNA is a good candidate because it is a pregnancy-specific polypeptide hormone produced by the placenta and is specifically expressed in the fetal syncytiotrophoblast.

We studied 43 pregnant women and 20 nonpregnant women who had previously given birth to at least one neonate. After receiving informed consent, we collected blood (2.5 mL) into PAXgene^TM tubes to reduce . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				S. Kumar and A. O'Brien Recent developments in fetal medicine BMJ, April 24, 2004; 328(7446): 1002 - 1006. [Full Text] [PDF]